Health
Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A – Science
SARS-CoV-2 viral proteins interact with the eukaryotic translation machinery and inhibitors of translation have potent antiviral effects. Here we report that the…
Abstract
SARS-CoV-2 viral proteins interact with the eukaryotic translation machinery and inhibitors of translation have potent antiviral effects. Here we report that the drug plitidepsin (aplidin), which has limited clinical approval, possesses antiviral activity (IC90 = 0.88 nM) 27.5-fold more potent than remdesivir against SARS-CoV-2 in vitro, with limited toxicity in cell culture. Through the use of a drug resistant mutant, we show that the antiviral activity of plitidepsin against SARS-CoV-2…
-
General11 hours agoPolice investigating after body found on road in Newborough, Gippsland
-
Noosa News22 hours agoDeaths of Karen Edwards, Tim Thomson, and Gordon Twaddle re-examined in inquest
-
Noosa News23 hours agoSecond inquest into homicide of three tourists shot dead Mount Isa in 1978 begins
-
General23 hours agoThe Church of England’s ‘turning point’ to irrelevancy